Structural highlights
Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
|
| Method: | X-ray diffraction, Resolution 2.5Å |
| Ligands: | , , , , , |
| Resources: | FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT |
Publication Abstract from PubMed
A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.
Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors.,Meden A, Knez D, Malikowska-Racia N, Brazzolotto X, Nachon F, Svete J, Salat K, Groselj U, Gobec S Eur J Med Chem. 2020 Aug 22;208:112766. doi: 10.1016/j.ejmech.2020.112766. PMID:32919297[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Meden A, Knez D, Malikowska-Racia N, Brazzolotto X, Nachon F, Svete J, Sałat K, Grošelj U, Gobec S. Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors. Eur J Med Chem. 2020 Dec 15;208:112766. PMID:32919297 doi:10.1016/j.ejmech.2020.112766
